Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease
Abstract
While significantly reduced glucose metabolism in fronto-temporo-parietal and cingulate cortices has been demonstrated in Alzheimer's disease (AD) compared with controls, cerebral glucose metabolism in patients with mild cognitive impairment who subsequently develop AD is less well-defined. In the present study we measured cerebral glucose metabolism by positron emission tomography (PET) with (18)F-2-fluoro-2-deoxy-D-glucose in 14 patients with aging-associated cognitive decline (AACD), 44 patients with AD, and 14 healthy control subjects at baseline. The AACD patients were clinically followed up, and conversion to AD was determined. Compared with controls, AACD patients had significantly reduced glucose metabolism in the right precuneus, posterior cingulate, right angular gyrus, and bilateral middle temporal cortices, while the respective deficits were more pronounced in AD patients and also involved the frontal cortices. AACD patients who subsequently converted to AD (AACD-converters) showed more extended metabolic changes which also involved the frontal and temporal cortices, right cingulate gyrus, right thalamus, and bilateral precuneus.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Individuals with MCI and early AD have diminished regional brain uptake of 2-DG, as measured by FDG-PET, before MCI-AD conversion, brain atrophy, or neurodegenerative changes.
“Individuals with MCI and early AD have diminished regional brain uptake of 2-DG, as measured by FDG-PET, before MCI-AD conversion, brain atrophy, or neurodegenerative changes (268, 345, 424, 425, 517).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [268]
Late-onset, sporadic AD is characterized with an early loss of BBB transporters including GLUT1 transporter for glucose.
“late-onset, sporadic AD is characterized with an early loss of BBB transporters including GLUT1 transporter for glucose (268, 424, 425, 345, 517)”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [268]
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works
Preclinical prediction of Alzheimer's disease using SPECT
Johnson, K. A., Jones, K., Holman, B. L., Becker, J. A., Spiers, P. A., Satlin, A., & Albert, M. S. (1998) · Neurology · doi:10.1212/wnl.50.6.1563 · Cited by 471 · see citing works
Nestor, P. J., Fryer, T. D., Ikeda, M., & Hodges, J. R. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02999.x · Cited by 227 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · see citing works
“…(FDG) have demonstrated that individuals diagnosed with aging-associated cognitive decline have significantly reduced glucose uptake in the right precuneus, posterior cingulate, right angular gyrus, and bilateral middle temporal cortices prior to conversion into AD (Hunt et al., 2007).”
2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212 · see citing works
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076 · see citing works
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969 · see citing works
“Studies using 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) have identified reductions in glucose uptake in asymptomatic individuals with a high risk of dementi”
Method2024 Alzheimer's disease facts and figures
(2024) · Alzheimer's & Dementia · doi:10.1002/alz.13809 · Cited by 2,536 · see citing works
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,294 · see citing works
2022 Alzheimer's disease facts and figures
Anonymous (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12638 · Cited by 2,384 · see citing works
Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease
Bell, R. D., & Zloković, B. V. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0522-3 · Cited by 855 · see citing works
“Studies using 2-[18F] fluoro-2-deoxy-D-glucose (FDG)PET, which measures cerebral glucose transport across the BBB, have shown reduction in cerebral glucose uptake in individuals with MCI or probable and possible AD prior to conversion to AD [26, 44].”
MethodThe blood-brain barrier in Alzheimer’s disease
Zenaro, E., Piacentino, G., & Constantin, G. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.007 · Cited by 767 · see citing works
“Several studies using F-2-fl uoro-2-deoxy-D -glu- cose-PET (FDG-PET) have demonstrated that MCI patients take up less glucose at the BBB, and FGD-PET may therefore be used as a marker for the preclinical diagnosis of AD (Hunt et al., 2007; Samuraki et al., 2007; Mosconi et al., 2008).”
The blood-brain barrier in aging and neurodegeneration
Knox, E. G., Aburto, M. R., Clarke, G., Cryan, J. F., & O’Driscoll, C. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01511-z · Cited by 738 · see citing works
Vascular dysfunction—The disregarded partner of Alzheimer's disease
Sweeney, M. D., Montagne, A., Sagare, A. P., Nation, D. A., Schneider, L. S., Chui, H. C., Harrington, M. G., Pa, J., Law, M., Wang, D. J. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.222 · Cited by 711 · see citing works
“cingulate, right angular gyrus, bilateral temporal cortices) before any detectable neurodegenerative changes, brain atrophy, and/or conversion to AD [82].”
The dynamic blood–brain barrier
Keaney, J., & Campbell, M. (2015) · The FEBS Journal · doi:10.1111/febs.13412 · Cited by 616 · see citing works
Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480 · see citing works
“Patient characteristics at baseline and 6 months are listed in Table 3.”
BackgroundEvidence for brain glucose dysregulation in Alzheimer’s disease
An, Y., Varma, V., Varma, S., Casanova, R., Dammer, E., Pletnikova, O., Chia, C. W., Egan, J. M., Ferrucci, L., Troncoso, J., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.09.011 · Cited by 454 · see citing works
Daulatzai, M. A. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23777 · Cited by 433 · see citing works
“frontal and temporal cortices, right cingulate gyrus, right thalamus, and bilateral precuneus (Hunt et al., 2007).”
BackgroundZhan, X.-H., Stamova, B., & Sharp, F. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00042 · Cited by 335 · see citing works
“Cerebral glucose metabolism is decreased in preclinical and prodromal AD before symptoms (Hunt et al., 2007; Herholz, 2010).”
BackgroundGlucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery
Patching, S. (2017) · Molecular Neurobiology · doi:10.1007/s12035-015-9672-6 · Cited by 315 · see citing works
Jacobs, H. I. L., Van Boxtel, M. P. J., Jolles, J., Verhey, F. R. J., & Uylings, H. B. M. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.06.009 · Cited by 293 · see citing works
Fan, Y., Resnick, S. M., Wu, X., & Davatzikos, C. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.02.043 · Cited by 288 · see citing works
“…flow or metabolic activity in AD patients (Foster et al., 1983; Ishii et al., 2005b; Kawachi et al., 2006; Koss et al., 1985; Martin et al., 1986) and in elderly individuals with cognitive decline (Hunt et al., 2007); however the biological underpinnings of these asymmetries are not quite known.”
BackgroundImpairing the Mitochondrial Fission and Fusion Balance: A New Mechanism of Neurodegeneration
Knott, A. B., & Bossy‐Wetzel, E. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.030 · Cited by 258 · see citing works
The Blood Brain Barrier in Neurodegenerative Disease: A Rhetorical Perspective
Carvey, P., Hendey, B., & Monahan, A. J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06319.x · Cited by 254 · see citing works
“…emission tomography (PET), a measure of cerebral glucose transport across the BBB, show a reduction in cerebral glucose uptake in patients with mild cognitive decline and possible AD prior to progression to AD (Drzezga et al. 2003; Hunt et al. 2007; Bell and Zlokovic 2009).”
BackgroundResultNeurovascular Dysfunction and Faulty Amyloid -Peptide Clearance in Alzheimer Disease
Sagare, A. P., Bell, R. D., & Zlokovic, B. V. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011452 · Cited by 251 · see citing works
“Several studies have suggested that reduced glucose uptake across the BBB as seen by FDG-PET can precede brain atrophy (Mosconi et al. 2006; Hunt et al. 2007; Samuraki et al. 2007; Mosconi et al. 2008; Herholz 2010) and may be used as a potential biomarker for AD (Miller 2009; Perrin et al. 2009).”
BackgroundInfluentialGlucose Transporters in Brain: In Health and in Alzheimer’s Disease
Szablewski, L. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160841 · Cited by 211 · see citing works
“PET imaging studies showed that altered glucose transport occurs early in AD [145].”
Ramanathan, A., Nelson, A. R., Sagare, A. P., & Zlokovic, B. V. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00136 · Cited by 205 · see citing works
“…by positron emission tomography (PET) using a glucose analog, 18F-2-fluoro-2-deoxy-D-glucose (FDG), is reported to be a forerunner to brain atrophy (Hunt et al., 2007), and has been observed in individuals with a genetic risk for AD, with a positive familial AD history, as well as those with none…”
BackgroundMethodKapasi, A., & Schneider, J. (2016) · Biochimica et Biophysica Acta · doi:10.1016/j.bbadis.2015.12.023 · Cited by 200 · see citing works
Zarei, M., Patenaude, B., Damoiseaux, J., Morgese, C., Smith, S. M., Matthews, P., Barkhof, F., Rombouts, S., Sanz-Arigita, E. J., & Jenkinson, M. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.09.001 · Cited by 199 · see citing works
“The posterior IML contains fibers that mainly connect the posterior parietal, precuneus, cuneus, and posterior cingulate to the pulvinar (Brun and Englund, 1981; Hunt et al., 2007).”
Hatt, M., Lee, J., Schmidtlein, C., Naqa, I. E., Caldwell, C., Bernardi, E. D., Lu, W., Das, S. K., Geets, X., Grégoire, V., et al. (2017) · Medical Physics (Lancaster) · doi:10.1002/mp.12124 · Cited by 186 · see citing works
Relative Intake of Macronutrients Impacts Risk of Mild Cognitive Impairment or dementia
Roberts, R., Roberts, L. A., Geda, Y., Cha, R., Pankratz, V., O'Connor, H. M., Knopman, D., & Petersen, R. C. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120862 · Cited by 170 · see citing works
“neuronal integrity, and neuronal function [9–11], rela-”
Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment
Gejl, M., Brock, B., Egefjord, L., Vang, K., Rungby, J., & Gjedde, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-17718-y · Cited by 163 · see citing works
Barone, E., Domenico, F. D., Perluigi, M., & Butterfield, D. (2021) · Free Radical Biology & Medicine · doi:10.1016/j.freeradbiomed.2021.09.006 · Cited by 155 · see citing works
Reddy, P. H. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.06.012 · Cited by 147 · see citing works
“Their observations suggest a mechanistic link between GSK3β activation and mitochondrial damage in PC12 cells treated with Aβ25–35 [128].”
BackgroundInfluentialRedzic, Z. B. (2011) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-8-3 · Cited by 128 · see citing works
Smailagic, N., Vacante, M., Hyde, C., Martin, S., Ukoumunne, O. C., & Sachpekidis, C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010632.pub2 · Cited by 229 · see citing works
Decoding microglial immunometabolism: a new frontier in Alzheimer's disease research
Jung, E. S., Choi, H., & Mook-Jung, I. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00825-0 · Cited by 124 · see citing works
“In AD, cerebral glucose metabolism declines significantly, a phenomenon strongly linked to cognitive impairment [119, 120].”
Morbelli, S., Piccardo, A., Villavecchia, G., Dessì, B., Brugnolo, A., Piccini, A., Caroli, A., Frisoni, G., Rodriguez, G., & Nobili, F. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1218-6 · Cited by 117 · see citing works
“Consistent with this hypothesis, recent papers have suggested a “compensatory response” in stable MCI patients, which fails in those who convert to AD [53, 54].”
ResultPeterson, C. W., Stoltzman, C. A., Sighinolfi, M. P., Han, K., & Ayer, D. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01613-09 · Cited by 97 · see citing works
“However, MondoA(1-400), which contains the MCR region, lacks an identifiable DNA binding domain and cannot activate a TXNIP luciferase reporter (data not shown).”
BackgroundAlzheimer's Disease: The Downside of a Highly Evolved Parietal Lobe?
Bruner, E., & Jacobs, H. I. L. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122299 · Cited by 87 · see citing works
“Furthermore, parietal lobe alterations could also have an impact on clinical practice, as hypometabolism in the medial parietal areas is more accurate in differentiating cognitively healthy older people from early AD patients than metabolic changes in other brain regions [34, 61–63].”
Yang, F.-Y., Lu, W.-W., Lin, W.-T., Chang, C.-W., & Huang, S.-L. (2015) · Brain Stimulation · doi:10.1016/j.brs.2014.11.017 · Cited by 87 · see citing works
Nitric Oxide and Mitochondrial Function in Neurological Diseases.
Ghasemi, M., Mayasi, Y., Hannoun, A., Eslami, S. M., & Carandang, R. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.02.017 · Cited by 84 · see citing works
Early Stages of Pathogenesis in Memory Impairment during Normal Senescence and Alzheimer's Disease
Daulatzai, M. A. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1374 · Cited by 82 · see citing works
“The most consistent hypometabolic region of the PCC was the retrosplenial cortex [20, 32,33].”
Labak, M., Foniok, T., Kirk, D., Rushforth, D., Tomanek, B., Jasiński, A., & Grieb, P. (2010) · Acta neurochirurgica. Supplementum · doi:10.1007/978-3-211-98811-4_32 · Cited by 79 · see citing works
“Several observations indicate that decrease in brain regional glucose consumption occurs very early in AD ( 5 ), and is not an artifact due to increase in extracellular fluid space induced by brain atrophy but a true metabolic reduction per gram of tissue (7).”
BackgroundPrincipal component analysis of FDG PET in amnestic MCI
Nobili, F., Salmaso, D., Morbelli, S., Girtler, N., Piccardo, A., Brugnolo, A., Dessì, B., Larsson, S., Rodriguez, G., & Pagani, M. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0869-z · Cited by 78 · see citing works
“This finding is in keeping with those of a recent paper on age-associated cognitive decline [16] and might suggest a compensatory recruitment in LFC in MCI/ MCI patients, which fails in those who convert to AD. Therefore, the posterior cingulate seems to show a more linear metabolic reduction from normal ageing to AD…”
ResultQuintessential Risk Factors: Their Role in Promoting Cognitive Dysfunction and Alzheimer’s Disease
Daulatzai, M. A. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0854-6 · Cited by 72 · see citing works
“AACD patients who subsequently converted to AD had more extensive glucose hypometabolic changes; in the frontal and temporal cortices, right cingulate gyrus, right thalamus, and bilateral precuneus [230, 232, 233].”
BackgroundInteractions between glial cells and the blood-brain barrier and their role in Alzheimer's disease
Zhao, M., Jiang, X., Zhang, H., Sun, J., Pei, H., Ma, L., Cao, Y., & Li, H. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101483 · Cited by 85 · see citing works
Koriyama, Y., Furukawa, A., Muramatsu, M., Takino, J., & Takeuchi, M. (2015) · Scientific Reports · doi:10.1038/srep13313 · Cited by 70 · see citing works
Cai, S.-P., Huang, L.-Y., Zou, J., Jing, L., Zhai, B., Ji, G.-J., von Deneen, K. V., Ren, J., & Ren, A.-F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0115573 · Cited by 68 · see citing works
“The thalamus pulvinar has widespread connectivity with the posterior parietal lobe and the PCu, which are pathological biomarkers in AD patients [47].”
BackgroundBeta2-Adrenergic Receptor and Astrocyte Glucose Metabolism
Dong, J., Chen, X., Cui, M., Yu, X., Pang, Q., & Sun, J.-P. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9742-4 · Cited by 65 · see citing works
Cerebrovascular plasticity: Processes that lead to changes in the architecture of brain microvessels
Bogorad, M. I., DeStefano, J. G., Linville, R. M., Wong, A. D., & Searson, P. C. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19855875 · Cited by 72 · see citing works
Modrego, P. J., Fayed, N. M., & Sarasa, M. (2011) · BMJ Open · doi:10.1136/bmjopen-2010-000007 · Cited by 56 · see citing works
Katt, M. E., Mayo, L. N., Ellis, S., Mahairaki, V., Rothstein, J. D., Cheng, L., & Searson, P. C. (2019) · Fluids and Barriers of the CNS · doi:10.1186/s12987-019-0139-4 · Cited by 69 · see citing works
Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation
Schöll, M., Almkvist, O., Axelman, K., Stefanova, E. D., Wall, A. E., Westman, E., Långström, B., Lannfelt, L., Graff, C., & Nordberg, A. K. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.016 · Cited by 56 · see citing works
The effect of aging on brain barriers and the consequences for Alzheimer’s disease development
Gorlé, N., Cauwenberghe, C. V., Libert, C., & Vandenbroucke, R. (2016) · Mammalian Genome · doi:10.1007/s00335-016-9637-8 · Cited by 55 · see citing works
A Comprehensive View on MRI Techniques for Imaging Blood-Brain Barrier Integrity.
Elschot, E. P., Backes, W., Postma, A., van Oostenbrugge, R. V., Staals, J., Rouhl, R., & Jansen, J. (2020) · Investigative Radiology · doi:10.1097/rli.0000000000000723 · Cited by 54 · see citing works
Butterfield, D., & Sultana, R. (2008) · Espert Review of Proteomics · doi:10.1586/14789450.5.2.157 · Cited by 54 · see citing works
“Since oxidatively modified proteins are generally dysfunctional [3,5,8–10], these findings are consistent with PET studies that demonstrate decreased energy metabolism in AD and mild cognitive impairment compared with that of the control [16, 17 ].”
Du, L., Liu, K., Zhu, L., Yao, X., Risacher, S., Guo, L., Saykin, A., & Shen, L. (2019) · Bioinform. · doi:10.1093/bioinformatics/btz320 · Cited by 52 · see citing works
Meta-analytic Comparison Between PIB-PET and FDG-PET Results in Alzheimer’s Disease and MCI
He, W., Liu, D.-H., Radua, J., Li, G., Han, B.-J., & Sun, Z.-G. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0138-7 · Cited by 50 · see citing works
Guenther, T., Schönknecht, P., Becker, G., Olbrich, S., Sander, C., Hesse, S., Meyer, P., Luthardt, J., Hegerl, U., & Sabri, O. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.01.059 · Cited by 47 · see citing works
“…rights reserved. memory impairment (Anchisi et al., 2005; Baxter, Jr. et al., 1989; Chetelat et al., 2003; Drzezga et al., 2003, 2005; Dubois et al., 2007; Fouquet et al., 2009; Herholz et al., 2002; Hunt et al., 2007; Mayberg et al., 1997, 2000; Mayberg, 2003; Schonknecht et al., 2009).”
Self-citationNeuroprotective and neurotrophic effects of long term lithium treatment in mouse brain
Riadh, N., Allagui, M., Bourogaa, E., Vincent, C., Croute, F., & Elfeki, A. (2011) · Biometals · doi:10.1007/s10534-011-9433-6 · Cited by 46 · see citing works
“In fact, glucose uptake and metabolism are impaired in Alzheimer disease brain and the reduction of cerebral glucose metabolism provides the earliest evidence of an ongoing neurodegenerative disease process (Hoyer 2004; Hunt et al. 2007).”
BackgroundPang, R., Wang, X., Pei, F., Zhang, W.-Z., Shen, J., Gao, X.-Q., & Chang, C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-190328 · Cited by 45 · see citing works
“Brain glucose metabolism dysregulation is one of the main features of AD [4, 5], and it is related to severity of AD pathology or symptom expression, such as cognitive impairment, accumulations of amyloid-(cid:2) (A (cid:2) ) peptide and neurofibrillary tangles [6], reduced brain synapses, and…”
Kowoll, M. E., Degen, C., Gorenc, L., Küntzelmann, A., Fellhauer, I., Giesel, F., Haberkorn, U., & Schröder, J. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00062 · Cited by 45 · see citing works
Self-citationMCI patients declining and not-declining at mid-term follow-up: FDG-PET findings.
Pagani, M., Dessì, B., Morbelli, S., Brugnolo, A., Salmaso, D., Piccini, A., Mazzei, D., Villavecchia, G., Larsson, S., Rodriguez, G., et al. (2010) · Current Alzheimer Research · doi:10.2174/156720510791162368 · Cited by 45 · see citing works
“In the majority of the studies, investigators have been looking for factors at baseline FDG-PET able to discriminate between converters and non-converters and to predict the course of the disease [2-6, 8].”
BackgroundDu, L., Liu, K., Yao, X., Risacher, S., Han, J.-W., Saykin, A., Guo, L., & Shen, L. (2019) · IEEE/ACM Transactions on Computational Biology & Bioinformatics · doi:10.1109/tcbb.2019.2947428 · Cited by 44 · see citing works
“For example, the significant reduction of glucose metabolism in the right angular gyrus has been observed in aging-associated cognitive decline (AACD) patients [34].”
BackgroundDrug Access to the Central Nervous System in Alzheimer’s Disease: Preclinical and Clinical Insights
Mehta, D. C., Short, J., Hilmer, S., & Nicolazzo, J. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1522-0 · Cited by 41 · see citing works
Diagnosis of Alzheimer’s Disease with [18F]PET in Mild and Asymptomatic Stages
Drzezga, A. (2009) · Behavioural Neurology · doi:10.3233/ben-2009-0228 · Cited by 41 · see citing works
Brain-targeting drug delivery systems.
Liu, P.-X., & Jiang, C. (2022) · Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1818 · Cited by 40 · see citing works
Crucial players in Alzheimer’s disease and diabetes mellitus: Friends or foes?
Kubis-Kubiak, A., Rorbach-Dolata, A., & Piwowar, A. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.03.008 · Cited by 46 · see citing works
Zhang, X.-Z., Li, G.-M., Guo, L., Nie, K., Jia, Y.-J., Zhao, L., & Yu, J. (2013) · Neurological Sciences · doi:10.1007/s10072-013-1407-8 · Cited by 37 · see citing works
“In addition to decreased CBF, the cerebral glucose transport across the BBB and the phosphorylation rates measured by FDG-PET were reduced in hypometabolic regions in MCI and AD patients [19–24].”
BackgroundOoi, C. P., Loke, S., Yassin, Z., & Hamid, T. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007220.pub2 · Cited by 35 · see citing works
Alzheimer’s Disease and Porphyromonas gingivalis: Exploring the Links
Shawkatová, I., Ďurmanová, V., & Javor, J. (2025) · Life · doi:10.3390/life15010096 · Cited by 35 · see citing works
Prospective classification of Alzheimer's disease conversion from mild cognitive impairment
Park, S., Hong, C., Lee, D.-G., Park, K., & Shin, H.-W. (2023) · Neural Networks · doi:10.1016/j.neunet.2023.04.018 · Cited by 34 · see citing works
“(2) PL angular gyrus L (PMID: 17524628) (Hunt et al., 2007) Compared with controls, aging-associated cognitive decline patients had significantly reduced glucose metabolism in the angular gyrus while the deficit were more pronounced in AD patients.”
Kriaučiūnaitė, K., Kaušylė, A., Pajarskienė, J., Tunaitis, V., Lim, D., Verkhratsky, A., & Pivoriūnas, A. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00871-w · Cited by 39 · see citing works
Does hyperglycemia downregulate glucose transporters in the brain?
Leão, L. L., Tangen, G., Barca, M., Engedal, K., Santos, S., Machado, F., de Paula, A. D., & Monteiro-Júnior, R. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109614 · Cited by 34 · see citing works
The Vascular-Immune Hypothesis of Alzheimer’s Disease
Mehta, R. I., & Mehta, R. I. (2023) · Biomedicines · doi:10.3390/biomedicines11020408 · Cited by 39 · see citing works
“18F-FDGPET imaging studies document decreased glucose uptake in specific brain regions during prodromal stages of AD [99].”
BackgroundAhmad, W., & Ebert, P. (2020) · Genes and Diseases · doi:10.1016/j.gendis.2020.08.004 · Cited by 30 · see citing works
Salcedo, C., Garcia, V. P., García‐Adán, B., Ameen, A. O., Gegelashvili, G., Waagepetersen, H. S., Freude, K., & Aldana, B. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16014 · Cited by 28 · see citing works
“Reduced glucose metabolism has been detected in the majority of clinically diagnosed AD patients, which precede the onset of dementia by several years (Hunt et al., 2007 ; Mosconi, 2013 ).”
BackgroundHaake, J., Meller, S., Meyerhoff, N., Twele, F., Charalambous, M., Talbot, S., & Volk, H. A. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1374511 · Cited by 27
“Metabolic changes in the aging brain, such as glucose hypometabolism and mitochondrial dysfunction, (4–7), and neuropathological findings, like the accumulation of ß42-amyloid plaques (8–13), and cerebral atrophy (14) may be associated with cognitive decline leading to typical clinical signs that…”
BackgroundClement, A., Wiborg, O., & Asuni, A. A. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00056 · Cited by 26 · see citing works
Hojjati, S. H., & Babajani-Feremi, A. (2022) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2021.769982 · Cited by 26 · see citing works
“It has been reported that AD patients have significantly reduced glucose metabolism in the angular gyrus, temporal gyrus, and posterior cingulate (Hunt et al., 2007).”
BackgroundModrego, P., & Fayed, N. (2011) · American Journal of Alzheimers Disease & Other Dementias · doi:10.1177/1533317511433809 · Cited by 26 · see citing works
“The voxel positioned in the posteromedial parietal cortex included the posterior cingulate gyrus, an area involved in early phases of AD according to PET studies.(31-33) This area is frequently explored in MRS studies and plays a pivotal role in memory as it is a part of the default mode network.”
MethodGibbs, M. E., Gibbs, Z., & Hertz, L. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05800.x · Cited by 26 · see citing works
“2003) which can be demonstrated even in patients ‘at risk’ for developing the disease (Hunt et al. 2007).”
BackgroundMitochondria in aging and age-associated diseases.
Pahal, S., Mainali, N., Balasubramaniam, M., Reis, R. S., & Ayyadevara, S. (2025) · Mitochondrion (Amsterdam. Print) · doi:10.1016/j.mito.2025.102022 · Cited by 25 · see citing works
LUPIEN, S. J., Lord, C., Sindi, S., Wilkinson, C. W., & Fiocco, A. J. (2009) · Elsevier eBooks · doi:10.1016/b978-008088783-8.00097-8 · Cited by 42 · see citing works
Fibrin-targeting immunotherapy for dementia
Kantor, A. B., Akassoglou, K., & Stavenhagen, J. B. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.105 · Cited by 24 · see citing works
“FDG-PET shows that GLUT1 levels are substantially diminished in brain micro-vessels in AD (19, 38), Moreover, imaging has revealed that patients with MCI have reduced glucose uptake in multiple brain areas prior to any apparent neurodegenerative changes, brain atrophy or conversion to AD (39, 40).”
BackgroundZedde, M., & Pascarella, R. (2024) · Brain Sciences · doi:10.3390/brainsci14100983 · Cited by 21 · see citing works
“Another interesting issue is related to the role of the amyloid beta (A β ) peptide in angiogenesis, which is frequently reported in the brain of AD patients in addition to neurodegeneration and neuroinflammation [152].”
BackgroundNutrients, Cognitive Function, and Brain Aging: What We Have Learned from Dogs
Pan, Y.-L. (2021) · Medical Science · doi:10.3390/medsci9040072 · Cited by 22 · see citing works
Schönknecht, O. D. P., Hunt, A. M., Toro, P., Guenther, T., Henze, M., Haberkorn, U., & Schröder, J. (2011) · Clinical EEG and Neuroscience · doi:10.1177/155005941104200207 · Cited by 20 · see citing works
Self-citationRecent advances in diagnostic and therapeutic strategies for canine cognitive dysfunction.
Kim, S. H., & Hao, J. (2025) · American Journal of Veterinary Research · doi:10.2460/ajvr.25.02.0053 · Cited by 19 · see citing works
Targeted Lipidomics of Mitochondria in a Cellular Alzheimer’s Disease Model
Kurokin, I., Lauer, A., Janitschke, D., Winkler, J., Theiss, E., Griebsch, L. V., Pilz, S. M., Matschke, V., van der Laan, M., Grimm, H., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9081062 · Cited by 19 · see citing works
5‐Methoxyindole‐2‐carboxylic acid (MICA) suppresses A&bgr;‐mediated pathology in C. elegans
Ahmad, W., & Ebert, P. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2018.04.021 · Cited by 19 · see citing works
Hao, L., Wang, L., Ju, M., Feng, W., Guo, Z., Sun, X., & Xiao, R. (2023) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2023.115649 · Cited by 18 · see citing works
Hypoperfusion is a potential inducer of immunosuppressive network in Alzheimer's disease
Salminen, A. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104919 · Cited by 20 · see citing works
Fast Multi-Task SCCA Learning with Feature Selection for Multi-Modal Brain Imaging Genetics
Du, L., Liu, K., Yao, X., Risacher, S., Han, J.-W., Guo, L., Saykin, A., & Shen, L. (2018) · IEEE International Conference on Bioinformatics and Biomedicine · doi:10.1109/bibm.2018.8621298 · Cited by 18 · see citing works
“Most importantly, these markers are all have been documented to be related to AD or MCI [21]–[25].”
BackgroundInfluentialDetecting dementia from written and spoken language
Masrani, V. (2018) · cIRcle (University of British Columbia) · doi:10.14288/1.0362923 · Cited by 18 · see citing works
“cortices) which can add evidence towards a diagnosis [24, 33, 60].”
BackgroundPetrovskaya, A. V., Tverskoi, A., Medvedeva, A., & Nazarova, M. (2023) · Communications Biology · doi:10.1038/s42003-023-04717-1 · Cited by 17 · see citing works
Hernandez, S. J., Fote, G. M., Reyes-Ortiz, A., Steffan, J. S., & Thompson, L. (2021) · Matrix Biology Plus · doi:10.1016/j.mbplus.2021.100089 · Cited by 17 · see citing works
“Patients with Alzheimer’s and Parkinson’s have reduced glucose transport [57,250,251] and the reduced ability to remove pharmaceuticals and xenobiotics via 15”
BackgroundQuaranta, D., Gainotti, G., Giuda, D. D., Vita, M., Cocciolillo, F., Lacidogna, G., Guglielmi, V., Masullo, C., Giordano, A., & Marra, C. (2018) · Psychiatry research. Neuroimaging · doi:10.1016/j.pscychresns.2017.10.008 · Cited by 16 · see citing works
The Role of Astrocytes and Blood–Brain Barrier Disruption in Alzheimer’s Disease
Cruz, J. V. R., Batista, C., Diniz, L., & Mendes, F. (2023) · Neuroglia · doi:10.3390/neuroglia4030015 · Cited by 15 · see citing works
“…hypoplasia The glucose transporter GLUT1 is also downregulated in AD brain ECs, causing decreased glucose uptake and LRP1 downregulation via sterol-binding protein-2 (SREBP2)-dependent transcription, resulting in A β accumulation [36]. and less LRP1-mediated Aβ clearance from the brain [35] .”
BackgroundApoE: The link between Alzheimer’s-related glucose hypometabolism and Aβ deposition?
Patil, S. P., Ballard, R., Sanchez, S., Osborn, J., & Santangelo, D. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.01.015 · Cited by 12 · see citing works
(18F)FDG-PET as a Biomarker for Early Alzheimer's Disease
Nobili, F., & Morbelli, S. (2010) · The Open Nuclear Medicine Journal · doi:10.2174/1876388x01002010046 · Cited by 13 · see citing works
Schönknecht, O. D. P., Hunt, A. M., Toro, P., Henze, M., Haberkorn, U., & Schröder, J. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.10.014 · Cited by 13 · see citing works
Self-citation
- Authors
- Hunt, A., Schönknecht, P., Henze, M., Seidl, U., Haberkorn, U., & Schröder, J.
- Affiliations
- Heidelberg University (DE)
- German Cancer Research Center (DE)
- Corresponding author
- Schröder, Johannes
- ORCID
- Schröder, Johannes
- Venue
- Psychiatry Research: Neuroimaging
- Publisher
- Elsevier BV
- Published
- 2007-07
- Volume
- 155
- Issue
- 2
- Pages
- 147-154
- ISSN
- 0925-4927 (ISSN-L)
- OpenAlex
- W2037603765
- Cited by
- 146
- References
- 41
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 9 · 2023: 16 · 2022: 5 · 2021: 9 · 2020: 6 · 2019: 9 · 2018: 9 · 2017: 7 · 2016: 10 · 2015: 5 · 2014: 5 · 2013: 4 · 2012: 8
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatry Research Neuroimaging (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, brain glucose metabolism, mild cognitive impairment, conversion to Alzheimer's disease, precuneus, posterior cingulate cortex, angular gyrus, middle temporal cortex, frontal cortex, thalamus, FDG-PET
- MeSH terms
- Aged, Alzheimer Disease, Brain, Brain Mapping, Cerebral Cortex, Cognition Disorders, Female, Follow-Up Studies, Frontal Lobe, Glucose, Gyrus Cinguli, Humans, Image Processing, Computer-Assisted, Functional Laterality, Male, Severity of Illness Index, Temporal Lobe, Tissue Distribution, Disease Progression, Fluorodeoxyglucose F18, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
